Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.315 EUR -1.1% Market Closed
Market Cap: 36.3m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Gensight Biologics SA
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Long-Term Debt
€16m
CAGR 3-Years
5%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Long-Term Debt
€187.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Long-Term Debt
€59.8m
CAGR 3-Years
-3%
CAGR 5-Years
-19%
CAGR 10-Years
48%
Inventiva SA
PAR:IVA
Long-Term Debt
€46.8m
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Long-Term Debt
€86.2m
CAGR 3-Years
90%
CAGR 5-Years
45%
CAGR 10-Years
22%
OSE Immunotherapeutics SA
PAR:OSE
Long-Term Debt
€40m
CAGR 3-Years
20%
CAGR 5-Years
46%
CAGR 10-Years
N/A
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
36.3m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.171 EUR
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's Long-Term Debt?
Long-Term Debt
16m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Long-Term Debt amounts to 16m EUR.

What is Gensight Biologics SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
18%

Over the last year, the Long-Term Debt growth was 167%. The average annual Long-Term Debt growth rates for Gensight Biologics SA have been 5% over the past three years , 18% over the past five years .

Back to Top